<DOC>
	<DOCNO>NCT01292928</DOCNO>
	<brief_summary>The primary objective clinical study determine whether Innova Stent System show acceptable performance long-term ( 12-month ) safety rate vessel patency treat femoropopliteal lesion .</brief_summary>
	<brief_title>SuperNOVA Clinical Stenting Trial</brief_title>
	<detailed_description>Atherosclerosis systemic disease become increasingly recognize expand elderly population significant cause morbidity mortality . Atherosclerosis vessel low extremity cause variety symptom range intermittent claudication ischemic rest pain critical ischemia major tissue loss . Typically , femoropopliteal lesion difficult successfully treat endovascular therapy disease often diffuse locate area body subject significant mobility stress extension , contraction , compression , elongation , flexion torsion . The SuperNOVA clinical study prospective , single arm , control , multicenter , global study . Approximately 50 center locate United States , Europe , Canada and/or Australia expect participate recruiting patient need treatment lesion femoropopliteal artery . A maximum 300 subject enrolled ensure minimum 296 stented segment treat Innova Stent System .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<criteria>1 . Subjects age 18 old 2 . Chronic symptomatic low limb ischemia define Rutherford categories 2 , 3 4 3 . Stenotic , restenotic ( angioplasty ) occlusive lesion ( ) locate native superficial femoral artery proximal popliteal artery : 1 . Degree stenosis &gt; /=70 % visual angiographic assessment 2 . Vessel diameter &gt; /= 4 &lt; /= 7mm 3 . Total lesion length ( series lesion ) &gt; /=30mm &lt; /= 190 mm ( note : tandem lesion may treat , provide tandem lesion segment cover one stent ) 4 . If lesion restenotic , PTA treatment must &gt; 3 month prior stent placement 5 . Target lesion locate least three centimeter inferior edge femur 4 . Patent infrapopliteal popliteal artery , i.e. , single vessel runoff well least one three vessel patent ( &lt; 50 % stenosis ) ankle foot 5 . Subject ( Legal Guardian ) willing able provide consent studyspecific test procedure perform agrees attend require followup visit 1 . Previous stent placement target vessel 2 . Subjects undergone prior surgery SFA/PPA target limb treat atherosclerotic disease 3 . Subjects undergone prior percutaneous transluminal angioplasty ( PTA ) target SFA/PPA past 3 month 4 . Use atherectomy device adjunctive treatment SFA/PPA index procedure 5 . History major amputation limb target lesion 6 . Life expectancy le 12 month due medical comorbid condition ( ) could limit subject 's ability participate clinical study , limit subject 's compliance followup requirement , impact scientific integrity clinical study 7 . Known hypersensitivity contraindication contrast dye , opinion investigator , adequately premedicated . 8 . Intolerance antiplatelet , anticoagulant , thrombolytic medication 9 . Platelet count &lt; 150,000 mm3 &gt; 600,000 mm3 10 . Concomitant renal failure serum creatinine &gt; 2.0 mg/dL 11 . Receiving dialysis immunosuppressant therapy 12 . Pregnancy 13 . Current participation another investigational drug device clinical study 14 . Known allergy Nitinol 15 . Septicemia time index procedure 16 . Presence hemodynamically significant outflow lesion require intervention within 30 day index procedure 17 . Target lesion within near aneurysm 18 . Acute ischemia and/or acute thrombosis SFA/PPA 19 . Persistent , intraluminal thrombus propose target lesion post thrombolytic therapy 20 . Perforated vessel evidence extravasation contrast medium 21 . Heavily calcified lesion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Atherosclerosis , Superficial Femoral Artery ( SFA ) , Proximal Popliteal Artery ( PPA ) , low extremity , Stenting</keyword>
</DOC>